


## Data Sheet

<b>Product Name:</b>	Costunolide
<b>Cat. No.:</b>	CS-1487
<b>CAS No.:</b>	553-21-9
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>20</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	232.32
<b>Target:</b>	Apoptosis; Endogenous Metabolite
<b>Pathway:</b>	Apoptosis; Metabolic Enzyme/Protease
<b>Solubility:</b>	Ethanol : 25 mg/mL (107.61 mM; ultrasonic and warming and heat to 60°C); DMSO : ≥ 49 mg/mL (210.92 mM)



### BIOLOGICAL ACTIVITY:

Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and **apoptosis** on breast cancer cells<sup>[1][2][3]</sup>. IC<sub>50</sub> & Target: Apoptosis<sup>[2][3]</sup> *In Vitro*: Costunolide inhibits the colony formation, migrative and invasive abilities of the H1299 cells in a dose or time dependent manner<sup>[2]</sup>.

Costunolide (6.7-215.2 μM; 24 hours) inhibits the viability of H1299 cells in a dose-dependent manner, with an IC<sub>50</sub> of 23.93 μM<sup>[2]</sup>.

Costunolide (12.0-48.0 μM; 48 hours) induces apoptosis in H1299 cells<sup>[2]</sup>.

Costunolide (12-48.0 μM; 6-12 hours) regulates metastasis- and proliferation-associated mRNA expression<sup>[2]</sup>.

Costunolide regulates epithelial-to-mesenchymal transition (EMT)-associated protein expression<sup>[2]</sup>.

Costunolide regulates c-Myc mediated apoptosis signaling and 14-3-3-mediated signaling pathways in breast cancer cells<sup>[3]</sup>.

*In Vivo*: Costunolide (20 mg/kg; i.p; daily; for 30 days) inhibits breast cancer through c-Myc/p53 and AKT/14-3-3 pathway<sup>[3]</sup>.

### References:

[1]. Dae Yong Kim, et al. Costunolide-A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential. Int J Mol Sci. 2019 Jun; 20(12): 2926.

[2]. Minyan Wei, et al. Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells. Oncol Rep. 2020 Jun;43(6):1986-1994.

[3]. Zhangxiao Peng, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.Sci Rep. 2017; 7: 41254.

### CAIndexNames:

Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, (3aS,6E,10E,11aR)-

### SMILES:

O=C1O[C@@]1([H])[C@@]2([H])CC/C(C)=C/CC/C(C)=C/1)C2=C

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA